- Title
- 204 Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study
- Creators
- Philip J. Mease - University of WashingtonChristopher T. Ritchlin - University of RochesterLaura C. Coates - University of OxfordAlexa P. Kollmeier - Johnson & Johnson (United States, Spring House)Bei Zhou - Johnson & Johnson (United States, Spring House)Yusang Jiang - Johnson & Johnson (United States, Spring House)Karen Bensley - Johnson & Johnson (United States, Spring House)Koeun Im - Johnson & Johnson (United States, Spring House)Rattandeep Batra - Johnson & Johnson (United States, Spring House)Soumya D. Chakravarty - Drexel UniversityProton Rahman - Memorial University of NewfoundlandDésirée van der Heijde - Leiden University Medical CenterJoseph F. Merola - The University of Texas Southwestern Medical Center
- Publication Details
- Journal of investigative dermatology, v 145(11), e63
- Publisher
- Elsevier
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Rheumatology; General Internal Medicine
- Other Identifier
- 991022130633704721
Abstract
204 Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study
Journal of investigative dermatology, v 145(11), e63
Nov 2025
Featured in Collection : Drexel's Newest Publications
Metrics
1 Record Views